Evidence map›Paper›PMID 42745055›Full record

ArticleNature medicine2026

Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS

Xinghao Ai, Zhengbo Song, Lin Wu, Aiping Zhou, Di Cheng, Hong Zong, Heshui Wu, Zuoxing Niu, Yuping Sun, Lingjun Zhu and 15 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Xinghao AiShanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhengbo SongPhase I Clinical Trial Ward, Zhejiang Cancer Hospital, Hangzhou, China.
Lin WuThe Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.ORCID http://orcid.org/0000-0001-7078-7767
Aiping ZhouDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Di ChengDepartment of Medical Oncology, Sun Yat-sen Memorial Hospital, Guangzhou, China.
Hong ZongDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Heshui WuDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zuoxing NiuDepartment of Phase I Clinical Trial Center/Department of Gastroenterology, Shandong Cancer Hospital, Shandong First Medical University, Jinan, China.
Yuping SunDepartment of Phase I Clinical Trial Center/Department of Gastroenterology, Shandong Cancer Hospital, Shandong First Medical University, Jinan, China.
Lingjun ZhuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhiwei LiDepartment of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China.
Yanhong DengDepartment of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ying YuanDepartment of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-3922-9553
Xiujuan QuDepartment of Gastroenterology, The First Hospital of China Medical University, Shenyang, China.
Haitao ZhaoDepartment of Liver Surgery, Peking Union Medical College Hospital/Chinese Academy of Medical Sciences, Beijing, China.ORCID http://orcid.org/0000-0002-3444-8044
Yingying DuDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ziming LiShanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu WangGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Haige ShenGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Huaqiang ZhuGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Chanli ZhengGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Shuang WangGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Zhao CuiGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Lingyu TaiGenFleet Therapeutics (Shanghai) Inc., Shanghai, China.
Shun LuShanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. shunlu@sjtu.edu.cn.ORCID http://orcid.org/0000-0001-8833-7262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kirsten rat sarcoma viral oncogene homolog (KRAS)

Indexed as

Carcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalColorectal NeoplasmsNeoplasmsProto-Oncogene Proteins p21(ras)Administration, OralAdultAgedAged, 80 and overFemaleHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedMutationKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID42745055

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.